Cummings, S.R., Black, M.D., Rubin, S.M., Lifetime risks of hip. Colles' or vertebral fracture rate and coronary heart disease among white postmenopausal women (1989) Arch Intern Med, 149, pp. 2445-2448
Autier, P., Haentjens, P., Bentin, J., Baillon, J.M., Grivegnee, A.R., Closon, M.C., Boonen, S., Costs induced by hip fractures: A prospective controlled study in Belgium (2000) Osteoporos Int, 11, pp. 373-380
Meta-analyses of therapies for postmenopausal osteoporosis (2002) Endocr Rev, 28, pp. 496-507
Kaufman, J.M., Body, J.J., Boonen, S., Devogelaer, J.P., Raeman, F., Rozenberg, S., Reginster, J.Y., L'ostéoporose involutive de la femme: Stratégie thérapeutique. Un point de vue actualisé du Belgian Bone Club (2000) Rev Med Liège, 55, pp. 443-448
Optimal calcium intake (1994) JAMA, 272, pp. 1942-1948. , NIH Consensus Conference Development panel on optimal calcium intake
Deprez, X., Fardellone, P., Nonpharmacologic prevention of osteoporotic fractures (2003) Joint Bone Spine, 70, pp. 448-457
Chapuy, M.C., Arlot, M.E., Duboeuf, F., Brun, J., Crouzet, B., Arnaud, S., Delmas, P.D., Meunier, P.J., Vitamin D3 and calcium to prevent hip fractures in the elderly women (1992) N Engl J Med, 327, pp. 1637-1642
Chapuy, M.C., Arlot, M.E., Delmas, P.D., Meunier, P.J., Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women (1994) BMJ, 308, pp. 1081-1082
Chapuy, M.C., Pamphile, R., Paris, E., Kempf, C., Schlichting, M., Arnaud, S., Garnero, P., Meunier, P.J., Combined calcium and vitamin D3 supplementation in elderly women: Confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: The Decalyos II study (2002) Osteoporos Int, 13, pp. 257-264
Dawson-Hughes, B., Harris, S.S., Krall, E.A., Dallal, G.E., Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older (1997) N Engl J Med, 337, pp. 670-676
Lips, P., Graafmans, W.C., Ooms, M.E., Bezemer, P.D., Bouter, L.M., Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial (1996) Ann Intern Med, 124, pp. 400-406
Trivedi, D.P., Doll, R., Khaw, K.T., Effect of four monthly oral vitamin D3 (cholecalciferol) supplementations on fractures and mortality in men and women living in the community: Randomised double blind controlled trial (2003) BMJ, 326, pp. 469-474
Heikinheimo, R.J., Inkovaara, J.A., Harju, E.J., Haavisto, M.V., Kaarela, R.H., Kataja, J.M., Kokko, A.M., Rajala, S.A., Annual injection of vitamin D and fractures of aged bones (1992) Calcif Tissue Int, 51, pp. 105-110
Consensus Development Conference on Osteoporosis (1993) Am J Med, 95 (5 A), pp. 1S-78S. , Hong Kong, April 1-2, 1993
Rozenberg, S., Vandromme, J., Kroll, M., Pastijn, A., Degueldre, M., Osteoporosis prevention with sex hormone replacement therapy (1994) Int J Fertil Menopausal Stud, 39, pp. 262-271
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial (2002) JAMA, 288, pp. 321-333
Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E., (1998) JAMA, 280, pp. 605-613
Skouby, S.O., Barlow, D., Samsioe, G., Gompel, A., Pines, A., Al-Azzawi, F., Graziottin, A., Rozenberg, S., Climacteric medicine: European Menopause and Andropause Society (EMAS) statements on postmenopausal hormonal therapy (2004) Maturitas, 48, pp. 19-25
Cauley, J.A., Robbins, J., Chen, Z., Cummings, S.R., Jackson, R.D., Lacroix, A.Z., Leboff, M., Watts, N.B., Effects of estrogen plus progestin on risk of fracture and bone mineral density (2003) JAMA, 290, pp. 1729-1738. , The Women's Health Initiative Randomized Trial
Alexandersen, P., Toussaint, A., Christiansen, C., Devogelaer, J.P., Roux, C., Fechtenbaum, J., Gennari, C., Reginster, J.Y., Ipriflavone Multicenter European Fracture Study Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial (2001) JAMA, 285, pp. 1482-1488
Alekel, D.L., St Germain, A., Peterson, C.T., Hanson, K.B., Stewart, J.W., Toda, Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women (2000) Am J Clin Nutr, 72, pp. 844-852
Hsu, C.S., Shen, W.W., Hsueh, Y.M., Yeh, S.L., Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density (2001) J Reprod Med, 46, pp. 221-226
Chen, Y.M., Ho, S.C., Lam, S.S., Ho, S.S., Woo, J.L., Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: A double-blind, randomized, controlled trial (2003) J Clin Endocrinol Metab, 88, pp. 4740-4747
Kreijkamp-Kaspers, S., Kok, L., Grobbee, D.E., De Haan, E.H., Aleman, A., Lampe, J.W., Van Der Schouw, Y.T., Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: A randomized controlled trial (2004) JAMA, 292, pp. 65-74
Nikander, E., Metsa-Heikkila, M., Ylikorkala, O., Tiitinen, A., Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer (2004) J Clin Endocrinol Metab, 89, pp. 1207-1212
Reginster, J.Y., Effect of calcitonin on bone mass and fracture rates (1991) Am J Med, 91 (SUPPL. 5B), pp. 19S-22S
Plosker, G.L., McTavis, D., Intranasal salcaltonin: A review of its pharmacological properties and role in the management of postmenopausal osteoporosis (1996) Drugs Aging, 8, pp. 378-400
Reginster, J.Y., Albert, A., Lecart, M.P., Lambelin, P., Denis, D., Deroisy, R., Fontaine, M.A., Franchimont, P., 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin (1987) Lancet, 1, pp. 1481-1483
Wallach, S., Effects of calcitonin on bone quality and osteoblastic function (1993) Calcif Tissue Int, 52, pp. 325-339
Silverman, S., Calcitonin (2001) Rheum Dis Clin North Am, 27, pp. 187-196
Carstens, J.H., Future horizons for calcitonin: A US perspective (1991) Calcif Tissue Int, 49 (2 SUPPL.), pp. S2-S6
Takahashi, S., Goldring, S., Katz, M., Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation (1995) J Clin Invest, 95, pp. 167-171
Cranney, A., Tugwell, P., Zytaruk, N., Robinson, V., Weaver, B., Shea, B., Wells, G., Guyatt, G., Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis (2002) Endocr Rev, 23 (4), pp. 540-551
Chestnut III, C.H., Silverman, S., Andriano, K., Genant, H., Giomona, A., Harris, S., Kiel, D., Baylink, D., A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fracture study (2000) Am J Med, 109, pp. 267-276. , PROOF Study Group
Hizmettli, S., Eiden, H., Kaptanoglu, E., Nacitarhan, V., Kocagil, S., The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis (1996) Int J Clin Pract, 52, pp. 453-455
Overgaard, K., Hansen, M.A., Jensen, S.B., Christiansen, C., Effect of salcaltonin given intranasally on bone mass and fracture rated in established osteoporosis: A dose-response study (1992) BMJ, 305, pp. 556-561
Gennari, C., Chierichetti, S.M., Bigazzi, S., Fusi, L., Gonnelli, S., Ferrara, R., Raccheif, Comparative effects on bone mineral content of calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis (1985) Curr Ther Res, 38, pp. 455-462
Rico, H., Revilla, M., Hernandez, E.R., Villa, L.F., Alverex De Buergo, M., Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study (1995) Calcif Tissue Int, 56, pp. 181-185
Kanis, J.A., Johnell, O., Gulberg, B.O., Allander, E., Dilsen, G., Gennari, C., Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture (1992) BMJ, 305, pp. 1124-1128
Riggs, B.L., Hartmann, L.C., Selective estrogen-receptor modulators - Mechanisms of action and application to clinical practice (2003) N Engl J Med, 348, pp. 618-629
Tamoxifen for early breast cancer: An overview of the randomised trials (1998) Lancet, 351, pp. 1451-1467
Ryan, W.G., Wolter, J., Bagdade, J.D., Apparent beneficial effect of tamoxifen on bone mineral content in patients with breast cancer: Preliminary study (1991) Osteoporos Int, 2, pp. 39-41
Lufkin, E.G., Whitaker, M.D., Nickelsen, T., Argueta, R., Caplan, R.H., Knickerbocker, R.K., Riggs, B.L., Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial (1998) J Bone Miner Res, 13, pp. 1747-1754
Ettinger, B., Black, D.M., Mitlak, B.H., Knickerbocker, R.K., Nickelsen, T., Genant, H.K., Christiansen, C., Cummings, S.R., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial (1999) JAMA, 282, pp. 637-645. , Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
Maricic, M., Adachi, J.D., Sarkar, S., Wu, W., Wong, M., Harper, K.D., Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis (2002) Arch Intern Med, 162, pp. 1140-1143
Delmas, P.D., Genant, H.K., Crans, G.G., Stock, J.L., Wong, M., Siris, E., Adachi, J.D., Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial (2003) Bone, 33, pp. 522-532
Siris, E., Adachi, J.D., Lu, Y., Fuerst, T., Crans, G.G., Wong, M., Harper, K.D., Genant, H.K., Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: Results from the MORE study (2002) Osteoporos Int, 13, pp. 907-913
Kanis, J.A., Johnell, O., Black, D.M., Downs Jr., R.W., Sarkar, S., Fuerst, T., Secrest, R.J., Pavo, I., Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial (2003) Bone, 33, pp. 293-300
Delmas, P.D., Ensrud, K.E., Adachi, J.D., Harper, K.D., Sarkar, S., Gennari, C., Reginster, J.Y., Eastell, R., Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial (2002) J Clin Endocrinol Metab, 87, pp. 3609-3617
Cummings, S.R., Karpf, D.B., Harris, F., Genant, H.K., Ensrud, K., Lacroix, A.Z., Black, D.M., Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive agents (2002) Am J Med, 112, pp. 281-289
Sarkar, S., Mitlak, B.H., Wong, M., Stock, J.L., Black, D.M., Harper, K.D., Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy (2002) J Bone Miner Res, 17, pp. 1-10
Bjarnason, N.H., Sarkar, S., Duong, T., Mitlak, B., Delmas, P.D., Christiansen, C., Six- and 12-month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis (2001) Osteoporos Int, 12, pp. 922-930
Cummings, S.R., Eckert, S., Krueger, K.A., Grady, D., Powles, T.J., Cauley, J.A., Norton, L., Jordan, V.C., The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation (1999) JAMA, 281, pp. 2189-2197
Barrett-Connor, E., Grady, D., Sashegyi, A., Anderson, P.W., Cox, D.A., Hoszowski, K., Rautaharju, P., Harper, K.D., Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE randomized trial (2002) JAMA, 287, pp. 847-857
Zimolo, Z., Wesolowski, G., Rodan, G.A., Acid extrusion is induced by osteoclast attachment to bone: Inhibition by alendronate and calcitonin (1995) J Clin Invest, 96, pp. 2277-2283
Frith, J.C., Mönkkönen, J., Blackbum, G.M., Russel, R.G.G., Rogers, M.J., Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(s-d-dichloromethylene) triphosphate, by mammalian cells in vitro (1997) J Bone Miner Res, 12, pp. 1358-1367
Luckman, S.P., Hughes, D.E., Coxon, F.P., Russell, R.G.G., Rogers, M.J., Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras (1998) J Bone Miner Res, 13, pp. 581-589
Body, J.J., Bisphosphonates as chemotherapeutic agents (2002) Curr. Opin. in Oncologic, Endocrine & Metabolic Investigational Drugs, 2, pp. 155-161
Harris, S.T., Watts, N.B., Jackson, R.D., Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis - Three years of blinded therapy followed by one year of open therapy (1993) Am J Med, 95, pp. 557-567
Kaufman, J.M., Devogelaer, J.P., Raeman, F., Rozenberg, S., Body, J.J., Westhovens, R., Reginster, J.Y., Prevention and treatment of postmenopausal osteoporosis national consensus of the "Belgian Bone Club" November (1996) Clin Rheumatol, 16, pp. 343-345
Liberman, U.A., Weiss, S.R., Broll, J., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis (1995) N Engl J Med, 333, pp. 1437-1443
Black, D.M., Cummings, S.R., Karpf, D.B., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures (1996) Lancet, 348, pp. 1535-1541
Cummings, S.R., Black, D.M., Thomson, D.E., Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the Fracture Intervention Trial (1998) JAMA, 280, pp. 2077-2082
Karpf, D.B., Shapiro, D.R., Seeman, E., Prevention of nonvertebral fractures by alendronate. A meta-analysis (1997) JAMA, 277, pp. 1159-1164. , Alendronate Osteoporosis Treatment Study Groups
Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Guyatt, G., Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women (2002) Endocr Rev, 23, pp. 508-516
Bone, H.G., Hosking, D., Devogelaer, J.P., Tucci, J.R., Emkey, R.D., Tonino, R.P., Rodriguez-Portales, J.A., Liberman, U.A., Ten years' experience with alendronate for osteoporosis in postmenopausal women (2004) N Engl J Med, 350, pp. 1189-1199
De Groen, P.C., Lubbe, D.F., Hirsch, L.J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Wang, K.K., Esophagitis associated with the use of alendronate (1996) N Engl J Med, 335, pp. 1016-1021
Schnitzer, T., Bone, H.G., Crepaldi, G., Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis (2000) Aging, 12, pp. 1-12. , Alendronate Once-Weekly Study Group. Milano
Harris, S.T., Watts, N.B., Genant, H.K., McKeever, C.D., Hangartner, T., Keller, M., Chesnut III, C.H., Miller, P.D., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial (1999) JAMA, 282, pp. 1344-1352
Reginster, J.Y., Minne, H.W., Sorensen, O.H., Hooper, M., Roux, C., Brandi, M.L., Lund, B., Eastell, R., Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis (2000) Osteoporos Int, 11, pp. 83-91. , Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
Watts, N.B., Josse, R.G., Hamdy, R.C., Hughes, R.A., Manhart, M.D., Barton, I., Calligeros, D., Felsenberg, D., Risedronate prevents new vertebral fractures in postmenopausal women at high risk (2003) J Clin Endocrinol Metab, 88, pp. 542-549
Sorensen, O.H., Crawford, G.M., Mulder, H., Kosking, D.J., Gennari, C., Mellstrom, D., Pack, S., Reginster, J.Y., Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience (2003) Bone, 32, pp. 120-126
Boonen, S., McClung, M., Eastell, R., Fuleihan, G., Barton, I., Delmas, P., Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women 80 years of age or older: Implications for the use of antiresorptive agents in the oldest old (2004) J Am Geriatr Soc, 52 (11), pp. 1832-1839
McClung, M.R., Geusens, P., Miller, P.D., Hip Intervention Program Study Group: Effect of risedronate on the risk of hip fracture in elderly women (2001) N Engl J Med, 344, pp. 333-340. , Hip Intervention Program Study Group
Cranney, A., Tugwell, P., Adachi, J., Weaver, B., Zytaruk, N., Papaioannou, A., Robinson, V., Guyatt, G., Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis (2002) Endocr Rev, 23, pp. 517-523
Brown, J.P., Kendler, D.L., McClung, M.R., Emkey, R.D., Adachi, J.D., Bolognese, M.A., Li, Z., Lindsay, R., The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis (2002) Calcif Tissue Int, 71, pp. 103-111
Boonen, S., Haentjens, P., Vandenput, Vanderschueren, D., Preventing osteoporotic fractures with antiresorptive therapy: Implications of microarchitectural changes (2004) J Intern Med, 255, pp. 1-12
Watts, N., Cooper, C., Lindsay, B., Eastell, R., Manhart, M., Barton, I., Van Staa, T., Adachi, J., Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk (2004) J Clin Densitom, 7, pp. 255-261
Chesnut III, C.H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J.A., Hoiseth, A., Felsenberg, D., Delmas, P.D., Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis (2004) J Bone Miner Res, 19, pp. 1241-1249
Reginster, J.Y., Taquet, A.N., Fraikin, G., Gosset, C., Zegels, B., Parathyroid hormone in the treatment of involutional osteoporosis: Back to the future (1997) Osteoporos Int, 7, pp. S163-167
Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Prince, R., Gaich, G.A., Reginster, J.Y., Hodsman, A.B., Mitlak, B.H., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis (2001) N Engl J Med, 344, pp. 1434-1441
Marcus, R., Wang, O., Satterwhite, J., Mitlak, B., The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis (2003) J Bone Min Res, 18, pp. 18-23
Lindsay, R., Scheels, W.H., Neer, R., Pohl, G., Adami, S., Mautalen, S.C., Reginster, J.Y., Mitlak, B.H., Sustained vertebral fracture risk reduction after withdrawal of teriparatide (recombinant human parathyroid hormone (1-34)) in postmenopausal women with osteoporosis (2004) Arch Int Med, 164, pp. 2024-2030
Body, J.J., Gaich, G.A., Scheele, W.H., Kulkarni, P.M., Miller, P.D., Peretz, A., Dore, R.K., Hodsman, A.B., A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone (1-34)) with alendronate in postmenopausal women with osteoporosis (2002) J Clin Endocrinol Metab, 87, pp. 4528-4535
Black, D.M., Greenspan, S.L., Ensrud, K.E., Palermo, L., McGowan, J.A., Lang, L.F., Garnero, P., Rosen, C.J., The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis (2003) N Engl J Med, 349, pp. 1207-1215
Kholsa, S., Parathyroid hormone plus alendronate - A combination that does not add up (2003) N Engl J Med, 349, pp. 1277-1279
Meunier, P.J., Slosman, D., Delmas, P., Sebert, J.L., Brandi, M.L., Albanese, C., Lorenc, R., Reginster, J.Y., Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis: A 2-year randomized placebo controlled trial (2002) J Clin Endocrinol Metab, 87, pp. 2060-2066
Reginster, J.Y., Spector, T., Badurski, J., Ortolani, S., Martin, T.J., Diez-Perez, A., Lemmel, E., Meunier, P.J., A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials (2002) Osteoporos Int, 13 (S1), pp. S30. , The Strontium Ranelate Phase III Program
Meunier, P.J., Roux, C., Seeman, E., Ortolani, S., Badurski, J.E., Spector, T., Cannata, J., Reginster, J.Y., The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis (2004) N Engl J Med, 350, pp. 459-468
Reginster, J.Y., Sawicki, A., Devogelaer, J.P., Padrino, J.M., Kaufman, J.M., Doyle, D.V., Fardellone, P., Meunier, P.J., Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis (2002) Osteoporos Int, 13 (S3), pp. O14
Rubin, L.A., Hawker, G.A., Peltekova, V.D., Fielding, L.J., Ridout, R., Cole, D.E., Determinants of peak bone mass: Clinical and genetic analyses in a young female Canadian cohort (1999) J Bone Miner Res, 14, pp. 633-643
Drake, A.J., Armstrong III, D.W., Shakir, K.M.M., Bone mineral density and total bone mineral content in 18-to-22-year-old women (2004) Bone, 34, pp. 1037-1043
Cooper, C., Barker, D.J.P., Wickham, C., Physical activity, muscle strength and calcium intake in fracture of the proximal femur in Britain (1988) BMJ, 297, pp. 1443-1446
Cummings, S.R., Nevitt, M.C., Browner, W.S., Stone, K., Fox, K.M., Ensrud, K.E., Risk factors for hip fracture in white women (1995) N Engl J Med, 332, pp. 767-773
Dargent-Molina, P., Favier, F., Grandjean, H., Baudoin, C., Schott, A.M., Hausherr, E., Fall-related factors and risk of hip fracture: The EPIDOS prospective study (1996) Lancet, 348, pp. 145-149
Albrand, G., Munoz, F., Sornay-Rendu, E., DuBoeuf, F., Delmas, P.D., Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: The OFELY Study (2003) Bone, 32, pp. 78-85
Jensen, J.E., Jensen, T.G., Smith, T.K., Johnston, D.A., Dudrick, S.J., Nutrition in orthopaedic surgery (1982) J Bone Joint Surg Am, 64, pp. 1263-1272
Hannan, M.T., Tucker, K.L., Dawson-Hughes, B., Cupples, L.A., Felson, D.T., Kiel, D.P., Effect of dietary protein on bone loss in elderly men and women: The Framingham osteoporosis study (2000) J Bone Miner Res, 15, pp. 2504-2512
Wengren, H.J., Munger, R.G., West, N.A., Cutler, D.R., Corcoran, C.D., Zhang, J., Dietary protein intake and risk of osteoporotic hip fracture in elderly residents in Utah (2004) J Bone Miner Res, 19, pp. 537-545
Neville, C.E., Murray, L.J., Boreham, A.G., Gallagher, A.M., Twisk, J., Robson, P.J., Relationship between physical activity and bone mineral status in young adults: The Northern Ireland young hearts project (2002) Bone, 30, pp. 792-798
MacKelvie, K.J., Petit, M.A., Khan, K.M., Beck, T.J., McKay, H.A., Bone mass and structure are enhanced following a 2-year randomized controlled trial of exercise in prepubertal boys (2004) Bone, 34, pp. 755-764
Danz, A.M., Zittermann, A., Schiedermaier, U., Klein, K., Hotzel, D., Schonau, E., The effect of a specific strength-development exercise on bone mineral density in perimenopausal and postmenopausal women (1998) J Women's Health, 7, pp. 701-709
Nelson, M.E., Fiatarone, M.A., Morganti, C.M., Trice, I., Greenberg, R.A., Evans, W.J., Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures (1994) JAMA, 272, pp. 1909-1914
Uusi-Rasi, K., Kannus, P., Cheng, S., Sievänen, H., Pasanen, M., Heinonen, A., Effect of alendronate and exercise on bone and physical performance of postmenopausal women: A randomized controlled trial (2003) Bone, 33, pp. 132-143
Uusi-Rasi, K., Sievänen, H., Heinonen, A., Kannus, P., Vuori, I., Effect of discontinuation of alendronate treatment and exercise on bone mass and physical fitness: 15-Month follow-up of a randomized, controlled trial (2004) Bone, 35 (3), pp. 799-805
Sinaki, M., Itoi, E., Wahner, H.W., Wollan, P., Gelzcer, R., Mullan, B.P., Stronger back muscles reduce the incidence of vertebral fractures: A prospective 10-year follow-up of postmenopausal women (2002) Bone, 30, pp. 836-841
Grisso, J.A., Kelsey, J.L., O'Brien, L.A., Miles, C.G., Sidney, S., Maislin, G., Risk factors for hip fracture in men (1997) Am J Epidemiol, 145, pp. 786-793. , Hip fracture study group
Grisso, J.A., Kelsey, J.L., Strom, B.L., Chiu, G.Y., Maislin, G., O'Brien, L.A., Risk factors for falls as a cause of hip fracture in women (1991) N Engl J Med, 324, pp. 1326-1331. , The Northeast Hip Fracture Study Group
Robertson, M.C., Campbell, A.J., Gardner, M.M., Devlin, N., Preventing injuries in older people by preventing falls: A meta-analysis of individual-level data (2002) J Am Geriatr Soc, 50, pp. 905-911
Schwartz, A.V., Kelsey, J.L., Sidney, S., Grisso, J.A., Characteristics of falls and risk of hip fracture in elderly men (1998) Osteoporos Int, 8, pp. 240-246
Lauritzen, J.B., Petersen, M.M., Lund, B., Effect of external hip protectors on hip fractures (1997) Lancet, 350, pp. 563-564
Kannus, P., Parkkari, J., Niemi, S., Pasanen, M., Palvanen, M., Jaarvinen, M., Prevention of hip fracture in elderly people with the use of a hip protector (2000) N Engl J Med, 343, pp. 1506-1513
Schoor, N.M., Smit, J.H., Twisk, J.W., Bouter, L.M., Lips, P., Prevention of hip fractures by external hip protectors: A randomized controlled trial (2003) JAMA, 289, pp. 1957-1962
Birks, Y.F., Hildreth, R., Campbell, P., Sharpe, C., Torgerson, D.J., Watt, I., Randomised controlled trial of hip protectors for the prevention of second hip fracture (2003) Age Ageing, 32, p. 442
